3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Pancreatic Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
CRC
1
Brain Neoplasms
1
Interventions
Temozolomide
46
Radiotherapy
36
Bevacizumab
34
Carmustine
13
Erlotinib Hydrochloride
11
Irinotecan
10
sargramostim
7
Thalidomide
7
Chemotherapy, Adjuvant
7
Carboplatin
7
Radiation
6
pembrolizumab
5
Topotecan
5
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Drug Therapy
5
Cyclophosphamide
5
aldesleukin
4
Tamoxifen
4
Surgical Procedures, Operative
4
Sorafenib
4
O(6)-benzylguanine
4
Gefitinib
4
Etoposide
4
Celecoxib
4
cediranib
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy, Conformal
3
Peripheral Blood Stem Cell Transplantation
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gliosarcoma
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled